The ECHS1 Knockout MES-OV Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian cancer cell line. This polyclonal product introduces targeted disruption of the ECHS1 gene, generating a heterogeneous loss-of-function model suitable for studying mitochondrial fatty acid oxidation in a cancer context. The use of a polyclonal population maintains some genetic diversity, reflecting potential phenotypic variations that can be useful for pooled screening or studying heterogeneous responses.
The MES-OV cell line was originally established from an ovarian endometrioid adenocarcinoma and is widely employed as an epithelial cancer model. MES-OV cells exhibit characteristics of ovarian cancer pathophysiology, making them a relevant host for investigating metabolic reprogramming and tumor cell survival mechanisms. The epithelial origin of this line supports studies related to ovarian cancer metabolism and therapeutic resistance.
ECHS1 encodes short-chain enoyl-CoA hydratase, which catalyzes the second step of mitochondrial fatty acid ??-oxidation by hydrating trans-2-enoyl-CoA intermediates to L-3-hydroxyacyl-CoA. This enzyme functions within a multienzyme complex that includes interacting partners HADHA and HADHB, and its activity is regulated by upstream factors such as PGC-1??, PPAR??, and AMPK signaling. Downstream, ECHS1 activity drives acetyl-CoA generation, supplying substrates for the TCA cycle and ATP synthesis. Disruption of ECHS1 impairs energy production from fatty acids and leads to accumulation of toxic intermediate metabolites, mirroring metabolic defects observed in ECHS1 deficiency and Leigh syndrome.
In ovarian cancer, fatty acid oxidation often supports tumor growth and survival, particularly under nutrient-depleted conditions. The ECHS1 knockout polyclonal MES-OV model enables the study of how loss of ECHS1 affects cellular metabolism, mitochondrial function, and cancer cell viability. This model may help elucidate metabolic vulnerabilities in ovarian tumors and serve as a system for investigating mitochondrial disease mechanisms in a cancer-relevant background.
Researchers can utilize these polyclonal knockout cells to perform functional assays such as radiolabeled palmitate oxidation measurements, Seahorse-based mitochondrial respiration profiling, ATP quantification, acyl-carnitine profiling via metabolomics, and viability assays under metabolic stress. The product is well-suited for exploring the role of fatty acid oxidation in cancer cell survival, screening of metabolic inhibitors, and modeling inherited ECHS1 deficiency in a human cellular context. For further details and custom inquiries, please contact Ascent Research.
